What is the recommended protocol for tapering off Paroxetine (Paxil)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tapering Off Paroxetine (Paxil)

Paroxetine should be tapered gradually over 10-14 days to minimize withdrawal symptoms, with a recommended reduction of 10% of the original dose per week as a starting point. 1, 2

Understanding Paroxetine Withdrawal

Paroxetine (Paxil) is a selective serotonin reuptake inhibitor (SSRI) that requires careful discontinuation due to its potential for causing withdrawal symptoms. Abrupt discontinuation can lead to significant withdrawal effects due to its relatively short half-life compared to other SSRIs 3.

Common withdrawal symptoms include:

  • Dysphoric mood, irritability, agitation 2
  • Dizziness, sensory disturbances (electric shock sensations, tinnitus) 2
  • Anxiety, confusion, headache 2
  • Emotional lability, insomnia 2
  • Abnormal dreams, paresthesia 2

Recommended Tapering Protocol

Initial Approach

  • Begin with a reduction of 10% of the original dose per week 1
  • For patients who have been on paroxetine for longer periods (years), consider slower tapers of 10% per month 1
  • Individualize the taper based on the patient's response and withdrawal symptoms 1

Step-by-Step Tapering Schedule

  1. First phase: Reduce by 10% of original dose weekly 1
  2. Adjustment phase: If withdrawal symptoms occur, slow the taper rate and hold at current dose until symptoms resolve 1
  3. Final phase: Once at lowest available dose, extend the interval between doses before stopping completely 1
  4. Completion: Paroxetine may be stopped when taken less frequently than once daily 1

Special Considerations

  • For patients on higher doses, consider slower tapers when reaching lower doses 1
  • Tapers may need to be paused and restarted when the patient is ready 1
  • Consider the taper successful as long as the patient is making progress 1

Managing Withdrawal Symptoms

Pharmacological Support

  • α2-Agonists like clonidine can help attenuate withdrawal symptoms (start with small doses due to potential hypotension) 1
  • Tizanidine is less effective but has lower risk of hypotension 1
  • For short-term use, consider trazodone, tricyclic antidepressants, gabapentin, or mirtazapine to manage anxiety, insomnia, and irritability 1
  • For gastrointestinal discomfort, loperamide may be helpful 1

Common Pitfalls to Avoid

  • Never discontinue paroxetine abruptly - this can lead to severe withdrawal symptoms 2
  • Avoid converting to methadone for weaning due to complex pharmacokinetics and high lethality risk 1
  • Don't use ultrarapid detoxification under anesthesia, which carries substantial risks including death 1
  • Be aware that withdrawal symptoms may be difficult to distinguish from recurrence of the original condition 1

Special Populations

Elderly Patients

  • Consider even slower tapers for elderly patients who may be more sensitive to withdrawal effects 1
  • Withdrawal should be more gradual, potentially extending over periods longer than one month 1
  • Monitor closely as elderly patients may experience more pronounced withdrawal symptoms 1

Pregnant Patients

  • Consult appropriate specialists before tapering during pregnancy due to risks to both mother and fetus 1
  • Opioid withdrawal during pregnancy has been associated with spontaneous abortion and premature labor, suggesting caution with any psychotropic withdrawal 1

Long-term Considerations

  • Be aware of potential protracted withdrawal symptoms that may occur months after discontinuation 1
  • These may include dysphoria, irritability, insomnia, anhedonia, or a vague sense of being unwell 1
  • Discuss with patients that these symptoms should be expected and can be treated 1
  • Warn patients about increased risk of overdose if they abruptly return to a previously prescribed higher dose 1

Remember that successful tapering is defined by patient progress, not necessarily by complete discontinuation within a specific timeframe 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Paroxetine: a review.

CNS drug reviews, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.